News - Immunologicals

Filter

Current filters:

Immunologicals

Popular Filters

1 to 25 of 136 results

Global regenerative medicine market expected to reach $67 billion by 2020

Global regenerative medicine market expected to reach $67 billion by 2020

15-07-2014

The global regenerative medicine market will reach $67.6 billion by 2020, up from $16.4 billion in 2013…

BiotechnologyGlobalImmunologicalsMarkets & MarketingRegenerative medicineResearchStem cells

Beike receives approval from Chinese FDA for umbilical stem cells in lupus

Beike receives approval from Chinese FDA for umbilical stem cells in lupus

10-07-2014

China-based stem cell research company Beike Biotechnology has been accepted into the approval process…

beikeBeike BiotechnologyBiotechnologyChinaGuangdong Food and Drug AdministrationImmunologicalsRegulationStem cells

Teijin inks exclusive deal with Sigma-Tau for EZN-2279 in Japan

Teijin inks exclusive deal with Sigma-Tau for EZN-2279 in Japan

26-06-2014

Japanese firm Teijin has entered into an agreement with the UK subsidiary of privately-owned Italian…

EZN-2279ImmunologicalsJapanLicensingPharmaceuticalSigma-TauTeijin

Ligand in licensing deal with TG Thera for IRAK-4 inhibitor program

Ligand in licensing deal with TG Thera for IRAK-4 inhibitor program

24-06-2014

US drugmaker Ligand Pharmaceuticals has signed an exclusive global license accord with TG Therapeutics…

ImmunologicalsLicensingLigand PharmaceuticalsOncologyPharmaceuticalTG Therapeutics

Array BioPharma inks deal with Biogen Idec on autoimmune disorders

Array BioPharma inks deal with Biogen Idec on autoimmune disorders

30-05-2014

US biotech firms Array BioPharma and Biogen Idec have entered into a collaboration for the discovery…

Array BioPharmaBiogen IdecBiotechnologyImmunologicalsLicensingResearch

MacroGenics and Takeda link up to develop DART for autoimmune disorders

27-05-2014

Privately held US biotech firm MacroGenics and Japan’s largest drugmaker Takeda Pharmaceutical have…

BiotechnologyImmunologicalsLicensingMacroGenicsMGD010Takeda Pharmaceutical

Eisai's R&D unit Kan Research Institute starts full-scale operation at new facility

27-05-2014

Japanese drug major Eisai Co says that its R&D subsidiary KAN Research Institute held a dedication ceremony…

BiotechnologyEisaiImmunologicalsJapanKan Research InstituteNeurologicalOncologyResearch

Positive opinion from CHMP for Veloxis’ Envarsus

22-05-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has today adopted…

EnvarsusEuropeImmunologicalsPharmaceuticalRegulationVeloxis Pharmaceuticals

FDA extends PDUFA date for Baxter and Halozyme’s HyQvia

21-05-2014

US drugmakers Baxter International and Halozyme Therapeutics revealed that the US Food and Drug Administration…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQviaImmunologicalsRegulationUSA

FDA approves Merck’s Ragwitek for short ragweed pollen allergies

18-04-2014

The US Food and Drug Administration has approved US pharma giant Merck & Co’s Biological License Application…

ALK AbelloImmunologicalsMerck & CoNorth AmericaPharmaceuticalRagwitekRegulationUSA

US FDA approves Stallergenes’ allergy tablet Oralair

US FDA approves Stallergenes’ allergy tablet Oralair

02-04-2014

The US Food and Drug Administration has approved Oralair immunotherapy tablet from French allergen specialist…

ImmunologicalsOralairPharmaceuticalRegulationStallergenesUSA

AnaptysBio and Tesaro team up in $340 million oncology deal

14-03-2014

Therapeutic antibody discoverer AnaptysBio announced a strategic immuno-oncology collaboration with fellow…

AnaptysBioBiotechnologyImmunologicalsLicensingOncologyTesaro

Sanofi and UCB in immune-mediated diseases research partnership

Sanofi and UCB in immune-mediated diseases research partnership

11-03-2014

French pharma major Sanofi and UCB, Belgium’s largest drugmaker, have entered into a scientific and…

Anti-Arthritics/RheumaticsGastro-intestinalsImmunologicalsPharmaceuticalResearchSanofiUCB

ALK’s partner for Japan reports positive trial results for house dust mite SLIT-tablet

10-03-2014

Denmark-based allergy specialist ALK Abello said that its Japanese partner Torii Pharmaceutical has reported…

ALK AbelloDenmarkImmunologicalsJapanPharmaceuticalResearchTorii Pharma

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

07-03-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has decided to award immunosuppressant drug…

Asia-PacificGenericsImmunologicalsMarkets & MarketingNew ZealandNovartisPricingSandozTacrolimus Sandoz

AAAAI 2014: Roche’s lebrikizumab shows reduction of asthma attack rates

AAAAI 2014: Roche’s lebrikizumab shows reduction of asthma attack rates

05-03-2014

Swiss drug major Roche has presented new data from the LUTE / VERSE Phase IIb studies for the investigational…

ImmunologicalslebrikizumabPharmaceuticalResearchRespiratory and PulmonaryRocheUSA

AAAAI 2014: Merck announces positive results of study in sublingual dust allergen immunotherapy tablet

AAAAI 2014: Merck announces positive results of study in sublingual dust allergen immunotherapy tablet

05-03-2014

Pharma giant Merck & Co has announced results from a Phase IIb study evaluating two doses of its investigational…

ImmunologicalsMerck & CoPharmaceuticalResearchUSA

Abide Therapeutics in deal with Celgene on immune disorders research

03-03-2014

Privately-held Abide Therapeutics has entered into a strategic collaboration with US biotech firm Celgene…

AB101131Abide TherapeuticsBiotechnologyCelgeneImmunologicalsInflammatory diseasesLicensingMergers & Acquisitions

Funding restrictions for rituximab and eltrombopag widened in New Zealand

Funding restrictions for rituximab and eltrombopag widened in New Zealand

20-02-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to widen…

Asia-PacificeltrombopagFinancialGlaxoSmithKlineHealthcareImmunologicalsNew ZealandPharmaceuticalrituximabRoche

1 to 25 of 136 results

Back to top